Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control comparison Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children

NCT02409277
View directory record Official record
Conditions
Asthma
Interventions
Experimental: Standard vs Intensive e-AT Intervention
Other
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 17 Years
Enrollment
926 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 22, 2026, 8:18 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy Between Serratus Plane Block And Local Infiltration In Vats

NCT03642457
View directory record Official record
Conditions
Lung Cancer
Interventions
Bupivacaine, Bupivacaine liposome
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437
View directory record Official record
Conditions
Breast Cancer
Interventions
ritonavir, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Expert Peer Facilitation of the EVERYbody Project

NCT05336253
View directory record Official record
Conditions
Body Image, Eating Disorder Symptom, Weight Bias
Interventions
EVERYbody Project-Connect, Self-Help Workbook
Behavioral
Lead sponsor
Western Washington University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bellingham, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

NCT03211234
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 22, 2026, 8:18 AM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 22, 2026, 8:18 AM EDT
Recruiting Not applicable Interventional

Leveraging the Emergency Department (LEAD) Study

NCT06605534
View directory record Official record
Conditions
Lung Cancer
Interventions
LungTalk, Non-tailored lung screening
Behavioral · Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Brick, New Jersey • Edison, New Jersey • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 22, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Opioid Sparing Pain Management Strategy

NCT04269109
View directory record Official record
Conditions
Cardiac Surgical Procedures
Interventions
Multi-modal Opioid Sparing Pain Management Protocol
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

NCT04524663
View directory record Official record
Conditions
Covid19
Interventions
Camostat Mesilate, Placebo, Standard of Care Treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 22, 2026, 8:18 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block

NCT02179892
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine Extended-Release Liposome Injection (Exparel), Bupivacaine and Dexamethasone Injection, IV Acetaminophen, Oral Acetaminophen
Drug
Lead sponsor
Colette Curtis MD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 4 Interventional Results available

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

NCT00357656
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Protein-Free Factor VIII (rAHF-PFM)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 22, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Accuracy of an Artificially-intelligent Stethoscope

NCT00564122
View directory record Official record
Conditions
Heart Murmurs, Congenital Heart Disease, Structural Heart Disease
Interventions
Artificially-Intelligent Stethoscope, Physical Examination
Device · Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Akron, Ohio • Beachwood, Ohio • Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

NCT00545857
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pioglitazone, Placebo control
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

NCT00368030
View directory record Official record
Conditions
Insomnia, Depressive Disorder, Major
Interventions
Eszopiclone, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
65
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Treatments for Post-traumatic Stress Disorder (PTSD) Sleep Disturbance

NCT00108628
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Imagery Rehearsal, Sleep and Nightmare Management
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 22, 2026, 8:18 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken

NCT05248737
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
DHA/EPA fortified chicken plus Placebo, non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement, non-DHA bio-enhanced chicken plus supplement DHA Omega-3, 25(OH)D bioenhanced chicken and eggs plus placebo, Dietary Supplement: DHA/EPA fortified eggs plus Placebo, non-DHA bio-enhanced eggs plus supplement DHA Omega-3, non-25(OH)D fortified chicken/eggs plus placebo
Dietary Supplement · Other
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resources to Enhance the Adjustment of Children (REACH)

NCT00820001
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Booster Treatment, No-Booster, No intervention, Treatment As Usual
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 22, 2026, 8:18 AM EDT
Active, not recruiting Not applicable Interventional

A Study Comparing the Effects of Two Types of Natural Oils Used in a Bedtime Foot Massage Routine on Sleep and Emotional Well-Being in Perimenopausal Women.

NCT07274371
View directory record Official record
Conditions
Sleep Disturbances in Perimenopause
Interventions
Brahmi-Gotukola oil padabhyanga, Sesame oil Padabhyanga
Behavioral
Lead sponsor
Saipriya Gowrishankar
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fairfield, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Not applicable Interventional

Pro-2-Cool Device Clinical Study

NCT03511339
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
TecTraum device
Device
Lead sponsor
TecTraum Inc.
Industry
Eligibility
12 Years to 21 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Ann Arbor, Michigan • Akron, Ohio • Boardman, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

NCT01899144
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax, ProAir HFA, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dental Plaque Prevention Efficacy of a Stannous Fluoride Toothpaste

NCT07419737
View directory record Official record
Conditions
Dental Plaque
Interventions
Stannous Fluoride Toothpaste (SnF), Sodium Fluoride Dentifrice
Drug
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 22, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 22, 2026, 8:18 AM EDT